CN113166235A - 抗体偶联物 - Google Patents

抗体偶联物 Download PDF

Info

Publication number
CN113166235A
CN113166235A CN201980076655.8A CN201980076655A CN113166235A CN 113166235 A CN113166235 A CN 113166235A CN 201980076655 A CN201980076655 A CN 201980076655A CN 113166235 A CN113166235 A CN 113166235A
Authority
CN
China
Prior art keywords
antibody
tau protein
conjugate
tau
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980076655.8A
Other languages
English (en)
Chinese (zh)
Inventor
G.詹尼斯
M.道威
石井雄一
冈田凉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Inc
Original Assignee
Fujirebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Inc filed Critical Fujirebio Inc
Publication of CN113166235A publication Critical patent/CN113166235A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
CN201980076655.8A 2018-11-22 2019-11-21 抗体偶联物 Pending CN113166235A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-219558 2018-11-22
JP2018219558 2018-11-22
PCT/JP2019/045589 WO2020105700A1 (ja) 2018-11-22 2019-11-21 抗体コンジュゲート

Publications (1)

Publication Number Publication Date
CN113166235A true CN113166235A (zh) 2021-07-23

Family

ID=70773827

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980076655.8A Pending CN113166235A (zh) 2018-11-22 2019-11-21 抗体偶联物

Country Status (5)

Country Link
US (1) US20220018856A1 (https=)
EP (1) EP3885362A4 (https=)
JP (2) JP7594913B2 (https=)
CN (1) CN113166235A (https=)
WO (1) WO2020105700A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115015228A (zh) * 2022-02-22 2022-09-06 上海科华生物工程股份有限公司 一种检测血液中p-tau181蛋白的化学发光试剂盒及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021065306A1 (ja) * 2019-09-30 2021-04-08 ニプロ株式会社 血液試料を検体とするタウタンパク質検出方法
CN113533746B (zh) * 2021-07-22 2022-05-10 深圳市天大生物医疗器械有限公司 一种P-Tau蛋白化学发光检测试剂盒及其制备方法
KR102888596B1 (ko) 2021-09-09 2025-11-20 알즈패스, 인크. 포스포-타우 항체 및 사용 방법
WO2026029079A1 (ja) * 2024-07-31 2026-02-05 富士レビオ株式会社 リン酸化タウタンパク質の測定方法およびリン酸化タウタンパク質の測定キット

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250600A2 (en) * 2000-01-24 2002-10-23 Innogenetics N.V. Diagnosis of tauopathies determining tau/phospho-tau ratio
CN102133410A (zh) * 2002-12-31 2011-07-27 免疫医疗公司 B细胞恶性瘤和自身免疫病的免疫疗法
JP2014523742A (ja) * 2011-07-14 2014-09-18 カソリック ウニヴェルシテイト ルーヴェン リン酸化タウ凝集体に対する抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69318420T2 (de) 1992-12-14 1999-01-28 Naamloze Vennootschap Innogenetics S.A., Gent Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
DK0737208T3 (da) 1993-12-21 2006-11-27 Innogenetics Nv Monoklonale antistoffer, der er specifikke for PHF-tau, hybridomaer, der secernerer dem, og antigen-genkendelse for disse antistoffer og deres anvendelsesmuligheder
WO2011109112A2 (en) 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
US20160356794A1 (en) * 2014-02-10 2016-12-08 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250600A2 (en) * 2000-01-24 2002-10-23 Innogenetics N.V. Diagnosis of tauopathies determining tau/phospho-tau ratio
CN102133410A (zh) * 2002-12-31 2011-07-27 免疫医疗公司 B细胞恶性瘤和自身免疫病的免疫疗法
JP2014523742A (ja) * 2011-07-14 2014-09-18 カソリック ウニヴェルシテイト ルーヴェン リン酸化タウ凝集体に対する抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EDWARD T.MAGGIO: "《Enzyme Immunoassay》", 18 January 2018, CRC出版集团, pages: 176 *
MIYEON LEE 等: ""Multivalent Antibody−Nanoparticle Conjugates To Enhance the Sensitivity of Surface-Enhanced Raman Scattering-BasedImmunoassays"", 《ACS APPL. MATER. INTERFACES》, vol. 10, pages 37829 - 37834 *
陈鸿斌 等: ""抗α干扰素双特异性抗体的制备与初步评价"", 《生物技术通讯》, vol. 28, no. 6, pages 742 - 749 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115015228A (zh) * 2022-02-22 2022-09-06 上海科华生物工程股份有限公司 一种检测血液中p-tau181蛋白的化学发光试剂盒及其制备方法

Also Published As

Publication number Publication date
JP2024178283A (ja) 2024-12-24
JPWO2020105700A1 (ja) 2021-10-07
JP7594913B2 (ja) 2024-12-05
EP3885362A1 (en) 2021-09-29
EP3885362A4 (en) 2022-08-17
US20220018856A1 (en) 2022-01-20
WO2020105700A1 (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
JP7594913B2 (ja) 抗体コンジュゲート
CA2480466C (en) Detection and/or monitoring of synuclein-related diseases
EP4130741B1 (en) Method for immunoassay of amyloid beta in blood, and kit for same
JP6713478B2 (ja) Ｐｉｖｋａ−ｉｉの測定方法、及びｐｉｖｋａ−ｉｉ免疫測定試薬又はキットの製造方法
EP3514539B1 (en) Cardiac troponin assay method and assay reagent
CN115728494A (zh) 一种胶质纤维酸性蛋白检测试剂盒及其制备方法
CN110133271B (zh) 一种将抗体或其抗原结合片段共价结合至颗粒表面的方法
JP7209498B2 (ja) Ｂ型肝炎ウイルスコア抗体の免疫測定方法
JPH1090269A (ja) 被検体の亜集団の測定のための均一検出方法
JP6048923B2 (ja) Ｂ型慢性肝炎の検出方法および検出キット
CN107973855A (zh) 与糖肽反应的单克隆抗体及其用途
CN101446586A (zh) 免疫分析试剂和分析方法
JP7680425B2 (ja) ヒトｉｖ型コラーゲン７ｓドメインを含む断片の測定方法及びこれに用いるためのキット
JP7590631B1 (ja) 肺サーファクタントプロテインｄの測定方法、測定キット、モノクローナル抗体及び細胞
JP7306661B2 (ja) 消化管間質腫瘍を検出する方法および検出試薬
CN112312921A (zh) 新型甲状腺过氧化物酶自身抗体免疫测定
HK1195617B (en) Immunoassay methods and reagents for decreasing nonspecific binding
JPH0552845A (ja) 免疫測定用試薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination